Compare FUSB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUSB | IMUX |
|---|---|---|
| Founded | 1952 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | FUSB | IMUX |
|---|---|---|
| Price | $13.53 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.3K | ★ 1.5M |
| Earning Date | 01-26-2026 | 02-14-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $36,068,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.30 | $0.54 |
| 52 Week High | $14.79 | $1.39 |
| Indicator | FUSB | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 30.10 |
| Support Level | $12.90 | $0.55 |
| Resistance Level | $13.71 | $0.60 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 41.47 | 2.23 |
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.